2017 9月 18
William Blair and BDA advise Olympus Partners on sale of Ritedose
Divested The Ritedose Corporation to AGIC and Humanwell
William Blair acted as the lead financial advisor to the Ritedose Corporation, a portfolio company of Olympus Partners, in connection with its sale to Humanwell Healthcare and AGIC Capital. The transaction closed on September 13 and represents one of 14 William Blair transactions in the pharmaceutical services space completed in the past 12 months. William Blair advised Ritedose on the transaction in conjunction with its Asian affiliate, BDA Partners.
- Deep sector expertise: Ritedose was attracted to William Blair and BDA’s extensive knowledge of the contract manufacturing and biopharmaceutical space, significant transaction experience with other outsourced pharmaceutical services companies, and strong relationships with potential buyers
- Process and execution excellence: William Blair and BDA designed and executed a highly competitive sale process with outreach to a global audience of highly interested strategic and financial buyers. This process drove a strong competitive dynamic, yielding an outstanding outcome and finding the right partner at a premium multiple for Ritedose
- Trusted guidance: William Blair and BDA’s transaction team was deeply involved in each step of the transaction process, including close collaboration with Ritedose in developing marketing materials, coordinating due diligence with multiple parties, and negotiating key contract terms
About Humanwell Healthcare
Humanwell Healthcare is a fully integrated China-based healthcare solutions provider. Since its establishment in 1993, Humanwell has endeavored to bring safe and effective medicines to the world through the quality of its products and integrity of its people.
Ritedose is the leading manufacturer of unit-dose sterile pharmaceutical products in the United States using Blow-Fill-Seal technology. The company produces about 1.0 billion units annually for the respiratory and ophthalmic markets through its contract manufacturing business and operating subsidiary Ritedose Pharmaceuticals. The Ritedose Corporation was founded in 1995 and is based in Columbia, South Carolina.
About AGIC Capital
Founded in 2015, AGIC Capital is an Asian buyout investor focused on European and U.S. middle-market companies in high-growth industries. AGIC invests in companies with high-value-add technologies that significantly increase industrial productivity and efficiency, enable new applications and manufacturing methods, and drive innovation for industrial products and solutions.
About Olympus Partners
Founded in 1988, Olympus Partners is a private equity firm focused on providing equity capital for middle-market management buyouts and for companies needing capital for expansion. Olympus is an active, long-term investor across a broad range of industries, including restaurants, consumer products, healthcare services, financial services, and business services. Olympus manages in excess of $5.5 billion on behalf of corporate pension funds, endowment funds, and state-sponsored retirement programs.
About William Blair
William Blair’s investment banking group enables corporations, financial sponsors, and owner/entrepreneurs around the world to achieve their growth, liquidity, and financing objectives. Drawing on the collective intellectual capital and deep sector expertise of a global team that reaches across more than 15 cities on four continents, the investment banking group brings a rigorous and innovative approach to corporate board advisory projects, mergers and acquisitions, and equity and debt financing. From 2012 to 2016, the team advised on more than $230 billion in completed transaction volume.
1William Blair made a minority investment in and entered into a strategic alliance with BDA Partners in order to offer clients our collective global reach.
Divested majority stake to DCP Capital
Agreed to divest Couvet, Switzerland facility to WuXi AppTec
Raised Series B round from ABC World Asia
Divested Neoss to CareCapital
Divested Escientia Life Sciences to Deccan Fine Chemicals
Divested significant stake in Kehua Bio-Engineering to Gree Real Estate
Divested LAP Laser to IK Investment Partners
Divested majority stake to The Longreach Group
Divested plant health business in Japan to Nisso
Majority recapitalized by Galen Partners
Divested CMC Biologics to Asahi Glass
Acquired Graphic Controls, USA
Divested to a Japanese chemicals & life science company
Sold stake in An Giang Plant Protection to Standard Chartered
Acquired Adval Tech Medical (Suzhou) and Omni Manufacturing (Mexico)
Divested Shanghai Elsker Mother & Baby Co. Ltd to Johnson & Johnson
Divested Radiant Research Inc, US-based clinical research company
Divested medical supply business to Halma in the UK
Established an animal vaccine JV with Jilin Guoyuan Animal Health
Acquired Lablndia distribution business in India